Cancer Therapy & Regenerative Medicine

As per the analysis, regenerative medicine market is expected to reach $79.23 billion by 2026. Approximately 53% of all current clinical trials on regenerative medicine are in oncology segment. There are many new breakthroughs that are currently being tested in clinal trials. Non-invasive cancer treatments like the use of radio waves or gold nanoparticles or carbon nanotubes to heat up tiny metals that are implanted into cancerous tissue, tumor treating fields, high-intensity focused ultrasound, etc are in the early developmental stage.

  • Track 1-1 CAR- T Cell Therapies
  • Track 2-2 CAR Macrophage Therapies
  • Track 3-3 Gamma Delta T-Cell Therapies
  • Track 4-4 iPSC-Derived T-Cell Therapies
  • Track 5-5 Natural Killer (NK) Therapies
  • Track 6-6 T-Cell Receptor (TCRs) Therapy
  • Track 7-7 Tumor-Infiltrating Lymphocytes (TILs) & Marrow-Infiltrating Lymphocytes (MILs)
  • Track 8-8 Gene Therapy
  • Track 9-9 Cell Therapy
  • Track 10-10 Oncolytic Viruses
  • Track 11-11 Hyperthermia
  • Track 12-12 Drug Therapy
  • Track 13-13 Bacterial Therapy

Related Conference of Oncology & Cancer